## Ganesh Cherala

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8941956/publications.pdf

Version: 2024-02-01

39 papers 1,075 citations

471509 17 h-index 395702 33 g-index

40 all docs

40 docs citations

times ranked

40

1469 citing authors

#	Article	IF	CITATIONS
1	Evaluation of the potential for pharmacokinetic interaction between tirabrutinib and levonorgestrel/ethinyl estradiol in healthy female volunteers. Clinical and Translational Science, 2022, , .	3.1	1
2	Double Dosing Levonorgestrel-Based Emergency Contraception for Individuals With Obesity. Obstetrics and Gynecology, 2022, 140, 48-54.	2.4	10
3	Revisiting contraceptive steroid hormone pharmacokinetics in obese women. Contraception, 2017, 95, 435-436.	1.5	O
4	Levonorgestrel butanoate intramuscular injection does not reliably suppress ovulation for 90 days in obese and normal-BMI women: a pilot study. Contraception, 2017, 95, 55-58.	1.5	3
5	Furosemide Pharmacokinetics in Adult Rats become Abnormal with an Adverse Intrauterine Environment and Modulated by a Postâ€Weaning Highâ€Fat Diet. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 432-439.	2.5	3
6	Obesity's effect on contraceptive failure is diluted by grouping of progestins. Contraception, 2016, 93, 565.	1.5	5
7	Impact of obesity on the pharmacokinetics of levonorgestrel-based emergency contraception: single and double dosing. Contraception, 2016, 94, 52-57.	1.5	64
8	The elusive minimum threshold concentration of levonorgestrel for contraceptive efficacy. Contraception, 2016, 94, 104-108.	1.5	22
9	Theophylline Pharmacokinetics in Foetal Sheep: Maternal Metabolic Capacity is the Principal Driver. Basic and Clinical Pharmacology and Toxicology, 2015, 117, 226-233.	2.5	1
10	How can we improve oral contraceptive success in obese women?. Expert Review of Clinical Pharmacology, 2015, 8, 1-3.	3.1	2
11	A phase II study of sulforaphane-rich broccoli sprout extracts in men with recurrent prostate cancer. Investigational New Drugs, 2015, 33, 480-489.	2.6	170
12	Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy. Contraception, 2015, 91, 71-75.	1.5	16
13	Lack of In Vitro–In Vivo Correlation of Adulthood Cytochrome P450 Activities in Low-Birth-Weight Rats. Drug Metabolism and Disposition, 2014, 42, 481-481.	3.3	O
14	Are children undergoing cardiac surgery receiving antibiotics at subtherapeutic levels?. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 1591-1596.	0.8	7
15	An Ethinyl Estradiol-Levonorgestrel Containing Oral Contraceptive Does Not Alter Cytochrome P4502C9 In Vivo Activity. Drug Metabolism and Disposition, 2014, 42, 323-325.	3.3	5
16	Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial. Contraception, 2014, 90, 550-556.	1.5	31
17	Perinatal growth restriction decreases diuretic action of furosemide in adult rats. European Journal of Pharmacology, 2014, 728, 39-47.	3.5	12
18	Effect of Protease Inhibitors on Steady-State Pharmacokinetics of Oral Norethindrone Contraception in HIV-Infected Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 72-77.	2.1	21

#	Article	IF	CITATIONS
19	Analysis of tacrolimus and creatinine from a single dried blood spot using liquid chromatography tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 926, 54-61.	2.3	74
20	Maternal low-protein diet alters the expression of real-time quantitative polymerase chain reaction reference genes in an age-, sex-, and organ-dependent manner in rat offspring. Nutrition Research, 2013, 33, 235-241.	2.9	10
21	Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users. Contraception, 2013, 87, 220-226.	1.5	43
22	Birthweight and cytochrome P4503A4/5 activity in obese women. British Journal of Clinical Pharmacology, 2013, 75, 275-276.	2.4	2
23	Clopidogrel variability: role of plasma protein binding alterations. British Journal of Clinical Pharmacology, 2013, 75, 1468-1477.	2.4	11
24	Contraceptive Failures in Overweight and Obese Combined Hormonal Contraceptive Users. Obstetrics and Gynecology, 2013, 122, 158-159.	2.4	7
25	Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women. British Journal of Clinical Pharmacology, 2012, 74, 510-514.	2.4	7
26	Aprepitant Pharmacokinetics and Assessing the Impact of Aprepitant on Cyclophosphamide Metabolism in Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation. Journal of Clinical Pharmacology, 2012, 52, 586-594.	2.0	27
27	Maternal obesity alters feto-placental cytochrome P4501A1 activity. Placenta, 2012, 33, 1045-1051.	1.5	18
28	Tacrolimus Pharmacokinetics in Hispanic Children After Kidney Transplantation. Transplantation Proceedings, 2011, 43, 3708-3712.	0.6	6
29	Application of platelet function testing to the bedside. Thrombosis and Haemostasis, 2010, 103, 29-33.	3.4	20
30	Pharmacokinetic study of lipoic acid in multiple sclerosis: comparing mice and human pharmacokinetic parameters. Multiple Sclerosis Journal, 2010, 16, 387-397.	3.0	52
31	Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception, 2010, 82, 314-323.	1.5	82
32	BMI, pharmacokinetics, and OCP failure. Contraception, 2010, 82, 582.	1.5	1
33	Maternal protein restriction during pregnancy and lactation in rats imprints long-term reduction in hepatic lipid content selectively in the male offspring. Nutrition Research, 2010, 30, 410-417.	2.9	30
34	Daptomycin Pharmacokinetics in Adult Oncology Patients with Neutropenic Fever. Antimicrobial Agents and Chemotherapy, 2009, 53, 428-434.	3.2	67
35	Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic–pituitary–ovarian activity. Contraception, 2009, 80, 119-127.	1.5	131
36	Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of "resistanceâ€. American Heart Journal, 2009, 158, 925-932.	2.7	64

#	Article	IF	CITATIONS
37	Pharmacokinetics of dehydroepiandrosterone and its metabolites after long-term oral dehydroepiandrosterone treatment in postmenopausal women. Menopause, 2009, 16, 272-278.	2.0	16
38	Effect of Perinatal Low Protein Diets on the Ontogeny of Select Hepatic Cytochrome P450 Enzymes and Cytochrome P450 Reductase in the Rat. Drug Metabolism and Disposition, 2007, 35, 1057-1063.	3.3	14
39	Two Low Protein Diets Differentially Affect Food Consumption and Reproductive Performance in Pregnant and Lactating Rats and Long-Term Growth in Their Offspring. Journal of Nutrition, 2006, 136, 2827-2833.	2.9	19